Lumos Pharma (LUMO) and Double Point Ventures announced the completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of $4.25 per share in cash at ...

AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment ...

DPV will acquire Lumos Pharma’s outstanding common stock shares for $4.25 per share payable in cash. The company will fund the transaction from its existing cash resources, with no financing ...

Lumos Pharma (LUMO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. This widely-known consensus outlook ...

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company ...

In September of 2019, NewLink Genetics and Lumos Pharma decided to merge. This ... Try a free 2-week trial today by clicking on our logo below! This article was written by.

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired ...

Lumos Pharma, Inc. (NASDAQ:LUMO) is not the least popular stock in this group but hedge fund interest is still below average. Our overall hedge fund sentiment score for LUMO is 24.

AUSTIN, Texas (AP) — AUSTIN, Texas (AP) — Lumos Pharma, Inc. (LUMO) on Tuesday reported a loss of $10.4 million in its first quarter. On a per-share basis, the Austin, Texas-based company said ...

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company that currently trades around a 50% discount to pro forma cash. The company is developing LUM-201 (oral ibutamoren) in pediatric ...

--Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johansson, M.D., to its Board of Directors ...